SitagliptinisapotentinhibitorofDPP4withIC₅₀of19nMinCaco-2cellextracts.

IC50:19nM(DPP4)

SitagliptinphosphateexhibitsapotentinhibitoryeffectonDPP-4withIC₅₀of19nMfromCaco-2cellextracts^[1]. SitagliptinreducesinvitromigrationofisolatedsplenicCD4T-cellsthroughapathwayinvolvingcAMP/PKA/Rac1activation^[2]. Stagliptinexertsanovel,directactioninordertostimulateGLP-1secretionbytheintestinalLcellthroughaDPP-4-independent,proteinkinaseA-andMEK-ERK1/2-dependentpathway.Itreducestheeffectofautoimmunityongraftsurvival^[3]. 

Invivo,theED₅₀valueofsitagliptinphosphateforinhibitionofplasmaDPP-4activityiscalculatedtobe2.3mg/kg7hourpostdoseand30mg/kg24hourpostdoseinfreelyfedHan-Wistarrats^[1]. Thestreptozotocin-inducedtype1diabetesmousemodelexhibitselevatedDPP-4levelsintheplasmathatcanbesubstantiallyinhibitedinmiceonanSitagliptinphosphatediet.Thisisachievedbyapositiveeffectontheregulationofhyperglycemia,potentiallythroughprolongationofisletgraftsurvival^[4]. TheplasmaclearanceandvolumeofdistributionofSitagliptinphosphatearehigherinrats(40-48mL/min/kg,7-9L/kg)thanindogs(9mL/min/kg,3L/kg);anditshalf-lifeisshorterinrats,2hourscomparedwith4hoursindogs^[5]. 

• [1].Thomas,L.,etal.(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione(BI1356),anovelxanthine-baseddipeptidylpeptidase4inhibitor,hasasuperiorpotencyandlongerdurationofacti

  [2].Kim,S.J.,etal.,DipeptidylpeptidaseIVinhibitionwithMK0431improvesisletgraftsurvivalindiabeticNODmicepartiallyviaT-cellmodulation.Diabetes,2009.58(3):p.641-51.

  [3].Sangle,G.V.,etal.,NovelBIOLOGicalactionofthedipeptidylpeptidase-IVinhibitor,sitagliptin,asaglucagon-likepeptide-1secretagogue.Endocrinology,2012.153(2):p.564-73.

  [4].Kim,S.J.,etal.,InhibitionofdipeptidylpeptidaseIVwithsitagliptin(MK0431)prolongsisletgraftsurvivalinstreptozotocin-induceddiabeticmice.Diabetes,2008.57(5):p.1331-9.

  [5].Beconi,M.G.,etal.Dispositionofthedipeptidylpeptidase4inhibitorsitagliptininratsanddogs.DrugMetabDispos,2007.35(4):p.525-32.

DPP-4isextractedfromconfluentCaco-2cells.After5minutesofincubationatroomtemperaturewithlysisbuffer(10mMTris-HCl,150mMNaCl,0.04U/mLaprotinin,0.5%NonidetP40,pH8.0),cellsarecentrifugedat35,000gat4°Cfor30minutes,andthesupernatantisstoredat-80°C.Assaysareperformedbymixing20μLofappropriatecompounddilutionswith50μLofthesubstratefortheDPP-4enzyme,H-Ala-Pro-7-amido-4-trifluoromethylcoumarin(finalconcentrationintheassay,100μM)and30μLoftheCaco-2cellextract(diluted1000-foldwith100mMTris-HCl,100mMNaCl,pH7.8).Platesareincubatedatroomtemperaturefor1hour,andfluorescenceismeasuredatexcitation/emissionwavelengthsof405/535nmusingaSpectraMaxGeminiXS.DissociationkineticsofinhibitorsfromtheDPP-4enzymeisdeterminedaftera1-hourpreincubationofCaco-2cellextractswithhighinhibitorconcentrations(30nMforBI1356,3μMforvildagliptin).TheenzymaticreactionisstartedbyaddingthesubstrateH-Ala-Pro-7-amido-4-trifluoromethylcoumarinaftera3000-folddilutionofthepreincubationmixturewithassaybuffer.Undertheseconditions,thedifferenceinDPP-4activityatacertaintimepointinthepresenceorabsenceofaninhibitorreflectstheamountofthisinhibitorstillboundtotheDPP-4enzyme.Maximalreactionrates(fluorescenceunits/seconds×1000)at10-minuteintervalsarecalculatedusingtheSoftMaxsoftwareoftheSpectraMaxandcorrectedfortherateofanuninhibitedreaction[(vcontrol-vinhibitor)/vcontrol].MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.

CD4T-cellsareplatedonmembraneinsertsinserum-freeRPMI1640,andcellmigrationisassayedusingTranswellchambers(Corning),inthepresenceorabsenceofpurifiedporcinekidneyDPP-4(32.1units/mg;100mU/mLfinalconcentration)andDPP-4inhibitor(100μM).After1hour,cellsontheuppersurfaceareremovedmechanically,andcellsthathavemigratedintothelowercompartmentarecounted.Theextentofmigrationisexpressedrelativetothecontrolsample.MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.

Sitagliptinisformulatedin0.5%aqueoushyroxyethylcellulose.

OvernightfastedC57BL/6Jmicearechallenged45minaftercompoundadministrationwithanoralglucoseload(2g/kg).Bloodsamplesforglucosemeasurementareobtainedbytailbleedpredoseandatserialtimepointsaftertheglucoseload.Toevaluatethedurationoftheeffectonglucosetolerance,vehicleorDPP-4inhibitorsareadministered16hbeforetheglucosechallenge.MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.

• [1].Thomas,L.,etal.(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione(BI1356),anovelxanthine-baseddipeptidylpeptidase4inhibitor,hasasuperiorpotencyandlongerdurationofacti

  [2].Kim,S.J.,etal.,DipeptidylpeptidaseIVinhibitionwithMK0431improvesisletgraftsurvivalindiabeticNODmicepartiallyviaT-cellmodulation.Diabetes,2009.58(3):p.641-51.

  [3].Sangle,G.V.,etal.,Novelbiologicalactionofthedipeptidylpeptidase-IVinhibitor,sitagliptin,asaglucagon-likepeptide-1secretagogue.Endocrinology,2012.153(2):p.564-73.

  [4].Kim,S.J.,etal.,InhibitionofdipeptidylpeptidaseIVwithsitagliptin(MK0431)prolongsisletgraftsurvivalinstreptozotocin-induceddiabeticmice.Diabetes,2008.57(5):p.1331-9.

  [5].Beconi,M.G.,etal.Dispositionofthedipeptidylpeptidase4inhibitorsitagliptininratsanddogs.DrugMetabDispos,2007.35(4):p.525-32.

407.31

C₁₆H₁₅F₆N₅O

486460-32-6

RoomtemperatureincontinentalUS;mayvaryelsewhere

10mMinDMSO

*"<1 mg/ml"="" means="" slightly="" soluble="" or="" insoluble.="" "≥"="" means="" soluble,="" but="" saturation="">

Purity:99.95%

SelectBatch:HY-13749-12715

DataSheet(123KB)SDS(120KB)

COA(94KB)HNMR(183KB)LCMS(197KB)

HandlingInstructions(1252KB)

• [1].Thomas,L.,etal.(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione(BI1356),anovelxanthine-baseddipeptidylpeptidase4inhibitor,hasasuperiorpotencyandlongerdurationofacti

  [2].Kim,S.J.,etal.,DipeptidylpeptidaseIVinhibitionwithMK0431improvesisletgraftsurvivalindiabeticNODmicepartiallyviaT-cellmodulation.Diabetes,2009.58(3):p.641-51.

  [3].Sangle,G.V.,etal.,Novelbiologicalactionofthedipeptidylpeptidase-IVinhibitor,sitagliptin,asaglucagon-likepeptide-1secretagogue.Endocrinology,2012.153(2):p.564-73.

  [4].Kim,S.J.,etal.,InhibitionofdipeptidylpeptidaseIVwithsitagliptin(MK0431)prolongsisletgraftsurvivalinstreptozotocin-induceddiabeticmice.Diabetes,2008.57(5):p.1331-9.

  [5].Beconi,M.G.,etal.Dispositionofthedipeptidylpeptidase4inhibitorsitagliptininratsanddogs.DrugMetabDispos,2007.35(4):p.525-32.

品牌介绍

托烷司琼临床评价药物相关作用适应症托烷司琼CAS号:89565-68-4英文名称:Tropisetron英文同义词:icf205-930;TROPICACID;TROPISETRON;SS-TROPISETRON;BETA-TROPISETRON;Tropisetron(ICS205930);TROPISHTRONHYDROCHLORIDE;Indole-3-carbonylchloride;3-Tropanylindole-3-carboxylate;lαH，5Αh-Tropan-3α-ylindole-3-carboxylate中文名称:托烷司琼中文同义词:托普西隆;托普西龙;曲匹西龙;托烷司琼;Β-托烷司琼;CS-348;Β-内托烷司琼;吲哚-3-甲酰氯;Β-托烷司琼(光学异构体);Β-托烷司琼,托烷司琼异构体CBNumber:CB3236404分子式:C17H20N2O2分子量:284.35MOLFile:89565-68-4.mol化学性质安全信息用途供应商112化学性质安全信息用途供应商112托烷司琼化学性质熔点:201-202°C沸点:448.5±35.0°C(Predicted)密度:1.26储存条件:2-8°C溶解度:H2O:soluble形态:solid酸度系数(pKa):15.38±0.30(Predicted)颜色:whiteCAS数据库:Chemicalbook89565-68-4(CASDataBaseReference)安全信息WGKGermany:3托烷司琼化学药品说明书托烷司琼|药物应用信息托烷司琼性质、用途与生产工艺临床评价Sorbe等报道本品对含顺铂(剂量50～89mg/m2)化疗方案引起的急性呕吐完全控制率为63%。58例恶性肿瘤化疗所致恶心、呕吐者，应用托烷司琼或昂丹司琼8mg分别在同一病人前后2个化疗周期的第1d给药前30min静脉注射，并用地塞米松10mg静脉滴注。结果两药控制急性及迟发性恶心、呕吐的疗效基本相似，均可达81%～100%。本品对强致吐化疗药物顺铂的止吐疗效突出。药物相关作用饮食可略为延长本品的吸收。本品与利福平、苯巴比妥等肝酶诱导药同时使用，可加快代谢，故快代谢型者需增加剂量，慢者则不必。西咪替丁等肝酶抑制药对本品血药浓度无明显影响。适应症托烷司琼临床用于预防和治疗癌症化疗引起的恶心和呕吐。化学性质结晶，熔点201-202℃(二氯甲烷-乙酸乙酯)。单盐酸托烷司琼(TropisetronMonohydroehloride)：C17H20N2O2?HCI。[105826-92-4]。熔点283-285℃(分解)。用途有高效性和选择性的5-HT3受体拮抗剂。用于化疗所致的呕吐。用途为5-羟色胺拮抗药生产方法托品醇(I)和酰氯(Ⅱ)反应，可得托烷司琼。托烷司琼上下游产品信息上游原料托品醇下游产品

公司介绍

托烷司琼临床评价药物相关作用适应症托烷司琼CAS号:89565-68-4英文名称:Tropisetron英文同义词:icf205-930;TROPICACID;TROPISETRON;SS-TROPISETRON;BETA-TROPISETRON;Tropisetron(ICS205930);TROPISHTRONHYDROCHLORIDE;Indole-3-carbonylchloride;3-

品牌分类

黄酮类化合物 抑制性抗体 苯丙素类 酸和醛 醌类 肽 其他 酚类 萜类和糖苷类

类固醇 生物碱 糖类和糖苷类 染料试剂 生化分析试剂

显示分类

联络我们

服务热线：4000-520-616

（限工作日9:00-18:00）

QQ ：1570468124

手机：18915418616

官网：http://www.medchemexpress.com/

快速导航：

公司介绍

产品中心

新闻动态

在线咨询

联系我们

公司介绍

产品中心

新闻动态

在线咨询

联系我们

总部地址：

江苏省苏州市工业园区星湖街218号 苏州生物医药产业园一期（生物纳米园）A4-216(邮编：215125)

工作时间：周一至周五9:00~18:00

技术支持：

Email：info@ebiomall.com

短信：18915418616

服务热线：

4000-520-616（全国）

☏  0512-67156496（苏州）

版权信息：

©  2015-2022 苏州蚂蚁淘生物科技有限公司 版权所有 中国

网站备案：

苏ICP备17049038号-1

苏公网安备 32059002001627号

友情链接：

联系QQ:764052152

medix代购 medkoo清关 megazyme正品 microspheres官网 midlandsci报价 minerva采购 molecular molinnov moltox mpbio ROMER中国 ​​polysciences药物筛选 Epigentek公司 Viskase价格 Apollo产品代理 美国Seracare immunologicals授权 蚂蚁淘 广东祺龙化玻仪器设备有限公司

免责声明：

本站有部分内容来自互联网，如无意中侵犯了某个媒体 、公司 、企业或个人等的知识产权，请来电或致函告之，
本网站将在规定时间内给予删除等相关处理。

扫描二维码关注官方微信

获取最新促销及产品信息